APOP - Cellect Biotechnology Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5450
-0.0530 (-8.86%)
At close: 2:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.5980
Open0.5700
Bid0.0000 x 1000
Ask0.0000 x 900
Day's Range0.5158 - 0.5700
52 Week Range0.5100 - 7.5000
Volume78,063
Avg. Volume111,932
Market Cap6.106M
Beta (3Y Monthly)2.25
PE Ratio (TTM)N/A
EPS (TTM)-0.8540
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
Trade prices are not sourced from all markets
  • PR Newswirelast month

    Cellect Biotechnology Reports First Quarter 2019 Financial and Operating Results

    TEL AVIV, Israel , May 21, 2019 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today reported financial ...

  • GlobeNewswirelast month

    Cellect Biotechnology to Explore Strategic Alternatives to Maximize Shareholder Value

    Following a review of its business, including the status of its clinical and development programs, resources and capabilities, Cellect Biotechnology Ltd. (APOP) plans to explore strategic alternatives focused on maximizing shareholder value.  Potential strategic alternatives that may be evaluated include, but are not limited to, an acquisition, merger, business combination, in-licensing, or other strategic transaction involving the Company or its assets. Due to a recent and unanticipated delay in the planned filing of the Company’s Investigational New Drug (IND) application for its human ApoGraft trial in the United States, the Company now believes the trial is expected to commence sometime during the first half of 2020, a delay of up to half a year.

  • GlobeNewswirelast month

    Cellect Biotechnology Announces Receipt of Nasdaq Minimum Bid Price Notification

    Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, announced today it has received notification from The Nasdaq Stock Market, LLC that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.

  • PR Newswire3 months ago

    Cellect Announces Positive Phase I/II Mid-Study Results of Its ApoGraft™ Technology

    TEL AVIV, Israel, March 27, 2019 /PRNewswire/ -- Further validating its ApoGraft™ technology, Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, announced positive mid-study data from the Company's Phase I/II study of its ApoGraft™ technology. Both, the principal investigator (PI) and independent data safety monitoring board (DSMB) agree that no serious adverse events (SAEs) reported during the course of the study were related to the ApoGraft™ process.

  • PR Newswire3 months ago

    Cellect Biotechnology Reports Fourth Quarter and Full Year 2018 Results and Recent Corporate Progress

    Milestone Execution Positions the Company for Expedited Progress in 2019 TEL AVIV, Israel , March 18, 2019 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of a novel stem cell production ...

  • ACCESSWIRE3 months ago

    Stem Cell Collaboration Results Push Cellect Biotechnology Shares Higher, Full Analysis

    NEW YORK, NY / ACCESSWIRE / March 12, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Cellect Biotechnology Ltd. (APOP) is a biotechnology company, focused on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. On March 11, 2019, Cellect Biotechnology, announced preliminary results from its collaboration with Cell2in, a privately-held South Korean company focused on improving the quality of stem cells.

  • ACCESSWIRE3 months ago

    Four Healthcare Stocks Making Moves on Monday

    CORAL GABLES, FL / ACCESSWIRE / March 11, 2019 / The future of the healthcare stock market, and the medical sector in its entirety, is largely dependent on whether medical experts and healthcare professionals are aptly prepared to meet the growing demands of patients. As companies in the healthcare sector work to develop innovative technologies for their patients, these efforts may create potential opportunities for investors looking to the industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Axovant Sciences Ltd (AXGT), Tonix Pharmaceuticals Holding Corp (TNXP), and Cellect Biotechnology Ltd (APOP) are 4 healthcare companies looking to kick off a strong week of trading.

  • PR Newswire3 months ago

    Cellect Announces Positive Results From Cell2in Collaboration Showing Significant Improvement in Expansion Rate and Function of Stem Cells

    Results and Validation of ApoGraft technology from a variety of sources could lead to a more cost-effective solution for the cell therapy industry. TEL AVIV, Israel, March 11, 2019 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, today announced positive preliminary results from its collaboration with Cell2in, a privately-held South Korean company focused on improving the quality of stem cells. Results of this third-party study further validate that Cellect's Apograft™ technology significantly improves both proliferation and functional capabilities of hematopoietic (HSC) and mesenchymal (MSC) stem cells originating from bone marrow, peripheral blood, umbilical cord, and adipose tissue.

  • GlobeNewswire4 months ago

    Cellect Announces Closing of $6.5 Million Underwritten Public Offering

    Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, today announced the closing of its previously announced $6.5 million underwritten public offering of 1,889,000 units, with each unit consisting of one American Depositary Share (ADS) and a warrant to purchase one ADS as well as 2,444,800 pre-funded units, with each pre-funded unit consisting of a pre-funded warrant to purchase one ADS and a warrant to purchase one ADS.  In addition, the underwriters partially exercised their overallotment option and purchased an aggregate of 350,000 additional ADS of the Company and additional warrants to purchase 650,070 ADSs of the Company, for total gross proceeds of approximately $7.0 million. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise.

  • GlobeNewswire5 months ago

    Cellect Announces Pricing of $6.5 Million Public Offering

    A.G.P./Alliance Global Partners is acting as the sole book-running manager for the offering. National Securities Corporation and Dawson James Securities, Inc. are acting as co-managers for the offering. The offering is expected to close on or about February 12, 2019, subject to customary closing conditions.

  • PR Newswire5 months ago

    Cellect Begins Collaboration with Washington University in Preparation for First U.S. Clinical Trial Using Cellect's ApoGraft™ for Bone Marrow Transplantations

    TEL AVIV, Israel and ST. LOUIS, Feb. 5, 2019 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, today announced a collaboration with Washington University, a leading academic institution based in St. Louis, MO, aimed at determining the safety and tolerability in a U.S. Phase I/II study using ApoGraft™ for bone marrow transplantations.  The collaboration is led by Dr. John DiPersio, Director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine and President of the American Society for Blood and Marrow Transplantation, and Dr. Mark Schroeder, an expert in bone marrow transplantation in the Division of Oncology at Washington University School of Medicine. This will be the first clinical trial in the U.S. using the Company's ApoGraft stem cell selection technology, which is designed to prevent acute graft-versus-host disease following bone marrow transplantation.  Previously, the Company has reported positive safety and tolerability data from an ongoing trial that is being performed outside the U.S., and expects to report additional interim results during the first half of 2019.  This open label clinical trial of twelve patients, expected to complete recruitment during the second quarter of 2019, is designed to evaluate the safety and tolerability of the ApoGraft™ process in patients with hematological malignancies who are undergoing an allogeneic hematopoietic stem cell transplantation (HSCT).

  • PR Newswire5 months ago

    Completion of Manufacturing of Clinical Grade FasL Enables Cellect to Expedite U.S. Clinical Programs into Multiple Studies

    Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, today announced it has concluded the scale-up development and manufacturing of clinical grade FasL in collaboration with its outsourced supplier. Based on its process and the results of the ongoing clinical trial, the Company has scaled up manufacturing of FasL for hundreds of personal batches fully scalable to hundreds of thousands of batches for clinical and collaborative purposes. The Company expects to form an alliance of clinical and commercial cell therapy centers using the ApoGraft™ technology.

  • PR Newswire5 months ago

    Cellect Biotechnology Reports Clinical and Regulatory Milestone Targets

    TEL AVIV, Israel, Jan. 23, 2019 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a novel regenerative and cell therapy company with production technology, today provided its milestone targets through the second quarter of 2020. The Company is currently in advanced discussions with a leading academic institution.

  • PR Newswire6 months ago

    Further to the Announcement of the Agreement Signed With the South Korean Cell2in: KORIL Approves Cellect's Grant Application

    Dr. Shai Yarkoni, Cellect CEO commented: "The grant approval by KORIL-RDF acknowledges the commercial and scientific potential that may arise from our collaboration with Cell2in. TEL AVIV, Israel, Dec. 17, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, announced that KORIL-RDF, has approved Cellect's grant application, submitted with Cell2in, a Korean cell therapy company with whom a collaboration agreement was signed recently.

  • GlobeNewswire7 months ago

    Investor Expectations to Drive Momentum within Atomera, YogaWorks, Cellect Biotechnology, Eyegate Pharmaceuticals, Zealand Pharma A/S, and Polar Power — Discovering Underlying Factors of Influence

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswire7 months ago

    Cellect Biotechnology Provides Corporate Update and Reports Third Quarter 2018 Financial Results

    TEL AVIV, Israel , Nov. 13, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today provided a corporate ...

  • PR Newswire8 months ago

    Cellect Receives Multiple Patent Grants

    Following US, EU, Russia and South Korean approval, Cellect Technology Patent has now also been approved in Japan and Australia Patent Covers First-in-kind Devices Using Cellect's Flagship Technology, ...

  • PR Newswire8 months ago

    Cellect to Present Its Breakthrough Stem Cell Production Technology at the BIO-Europe

    TEL AVIV, Israel, Nov. 1, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP) , a developer of a novel stem cell production technology, announced today its CEO Dr. Shai Yarkoni will present at the 24th Annual Bio Europe Conference  which is being held in Copenhagen, Denmark from November 5-7, 2018. Dr. Yarkoni will present as part of the Cell and Gene Therapies track on Tuesday, November 6 at 10:15 am. "Our ApoGraft™ technology is designed to enable stem cell companies around the world to manufacture and perform safer and more cost effective stem cell-based therapeutics.

  • PR Newswire8 months ago

    Cellect Announces a Major Technological Breakthrough for Industrialization of Apotainer™ Stem Cell Product Line

    TEL AVIV, Israel, Oct. 22, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell isolation technology, announced that it has successfully developed for industrialization its first in kind new technology as an integral part of Cellect's ApoTainer™. The new technology utilizes FasL-coated magnetic beads for maximizing efficacy and scalability of stem cell-based products' manufacturing.

  • PR Newswire8 months ago

    Positive Results of Orthopedic Treatment With the Use of ApoGraft™ Enriched Stem Cells Derived From Fat Tissues

    Such stem cell enrichment products may create a dramatic change in orthopedic treatments and be used during surgical procedures and under cost effective conditions. TEL AVIV, Israel, Oct. 18, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a developer of stem cell selection technology, announced today that it has achieved positive results on the use of human fat derived stem cells (mesenchymal) treated with the ApoGraft™ process in orthopedic treatments of animals. The study used ApoGraft enriched human mesenchymal stem cells at the time of surgery with the aim of improving the post-surgery healing process.

  • PR Newswire8 months ago

    Cellect Announces Positive Clinical Results

    TEL AVIV, Israel, Oct. 15, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, announced today further data from a Phase I/II study of its ApoGraft™ technology. With half of the patients planned for the study having finished first month follow up, all such patients have shown 100% engraftment with no procedure related adverse events reported. Further to the six patients' one month data detailed above, Cellect reports that the first three patients of the trial (cohort I) have completed the study period (180 days) with full safety and tolerability.

  • PR Newswire10 months ago

    Cellect Receives Notice of Allowance for Stem Cell Selection Technology Patent in Korea

    TEL AVIV, Israel, Aug. 20, 2018 /PRNewswire/ --  Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, announced today it has received a Notice of Allowance from the Korean Intellectual Property Office for its patent titled, "Devices and Methods for Selecting Apoptosis-Signaling Resistant Cells, and Uses Thereof". This patent, recently granted to Cellect in Europe, addresses the Company's ApoTainer™ device which is used in conjunction with its platform ApoGraft™ technology.

  • PR Newswire10 months ago

    Cellect and Cell2in Launch Collaboration to Significantly Improve Stem Cell Selection and Expansion

    TEL AVIV, Israel, Aug. 13, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, announced today that it has signed a collaboration agreement with Cell2in, a South Korean company focused on improving the quality of cells. Cell2in's FreSHtracer™ technology and its unique characteristics may improve the functionality and efficacy of Cellect's ApoGraft™ technology through the selection of desirable stem cells and quantification of the expansion process. Better quantification of quality stem cells is expected to lead to continuous improvements in Cellect's technology platform.

  • PR Newswire11 months ago

    Cellect Biotechnology Provides Corporate Update and Reports Second Quarter 2018 Financial Results

    TEL AVIV, Israel , Aug. 9, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today provided a corporate ...

  • PR Newswire11 months ago

    Cellect Granted Key European Patent for Its Stem Cell Selection Technology

    TEL AVIV, Israel, Aug. 7, 2018  /PRNewswire/ -- Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, announced today the European Patent Office has granted the company a patent for its platform ApoGraft™ technology and ApoTainer™ device titled, "Devices and Methods for Selecting Apoptosis-Signaling Resistant Cells, and Uses Thereof". Through negative selection, Cellect's technology identifies mature cells that can be harmful to the recipient and selectively eliminates those cells through apoptosis (cell death).